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sure and volume which increases LA size and promotes blood 
stasis. Loss of coordinated LA contraction further leads to 
blood stasis in the LA and left atrial appendage (LAA) which 
predisposes to thrombus formation (Figure 1). LA inflammation, 
atrial fibrosis and myocyte atrophy result in shortening of the 
atrial action potential and refractory periods which predispose 
to re-entrant circuits and AF (Figure 2).(9)
Increasing LA size and multivalvar involvement have been 
shown to be important clinical predictors of AF and thrombus 
formation.(4,10,11) The mean reported LA sizes ranged from 
4.3 - 5.7cm in these studies. In Wood’s series, AF occurred in 
29% of patients with isolated MS compared to 70% of 
patients with mixed mitral valve disease and tricuspid regur-
gitation. Valve severity, determined by mitral valve area at 
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INTRODUCTION
Rheumatic heart disease (RHD) is an important cause of 
morbidity and mortality worldwide.(1) In low and middle income 
countries, the incidence of acute rheumatic fever (ARF) remains 
relatively high (>1 per 10 000 people per year).(2) The pre-
valence of chronic RHD, the legacy of ARF, continues to rise in 
all regions of the world, except Europe and parts of the 
Americas.(3)
Atrial fibrillation (AF) is a major complication of chronic RHD. 
AF develops in approximately 18 - 39% of RHD patients and 
increases the risk of thromboembolism.(4,5) In low and middle 
income regions, like Africa and India, RHD still accounts for 
22 - 32% of all AF patients presenting to an emergency room 
and 3 - 8% of all strokes in China.(6,7) 
This review will highlight the pathogenesis and epidemiology of 
RHD, AF and thromboembolism and discuss the evidence for 
antithrombotic therapy and rhythm control strategies. 
PATHOGENESIS OF RHD, AF AND 
THROMBOEMBOLISM 
Acute rheumatic fever (ARF) is caused by a group A 
streptococcal infection of the tonsillo-pharynx.(8) Molecular 
mimicry between streptococcal M proteins and host tissue 
results in auto-antibody formation against cardiac endothelium, 
lamina, and the laminar basement membrane which results in a 
pancarditis and fibrosis of the heart valves. Mitral valve disease 
(particularly mitral stenosis (MS)) increases left atrial (LA) pres-
Thromboembolism, secondary to rheumatic atrial fi bril-
lation, remains an important cause of stroke and systemic 
embolism in low and middle income countries. This 
review will highlight the pathogenesis of rheumatic atrial 
fi brillation and thromboembolism. The risk factors and 
prevention of thromboembolism, including management 
strategies of rheumatic atrial fi brillation, will also be 
discussed.  SAHeart 2015;12:152-155
FIGURE 1: A transesophageal echocardiogram of a 
patient with mitral stenosis and atrial fibrillation.
This high-oesophageal view shows a large thrombus in the left 
atrial appendage with spontaneous echo contrast in the enlarged 
left atrium.
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cardiac catheterisation, or mean diastolic gradient by echo-
cardiogram were not predictors of the development of AF in 
any of these studies.
RISK OF THROMBOEMBOLISM IN AF
The risk of rheumatic AF and thromboembolism has always 
been thought to be high, based on old natural history studies of 
MS. In 2 old retrospective studies of MS and AF, thrombo-
emboli occurred in 22 - 32% of all patients with MS and AF 
compared to 6 - 8% of patients with MS and sinus rhythm.(11,12) 
In Wood’s series, thromboembolic episodes were cerebral in 
75%, peripheral in 33% and visceral in 6%; 22% of patients had 
both cerebral and peripheral emboli. It was also noted that 
MS carried a higher risk (HR 1.5) of thromboembolism com-
pared to mitral regurgitation (MR). This was also observed by 
Coulshed who reported that 32% of MS cases with AF develop 
thromboembolism compared to 22% of MR cases with AF 
between 1 and 13 years of follow-up.  
There have been 2 old prospective studies of RHD which have 
reported incidence rates of thromboembolism in patients with 
AF.(13,14) Szekely reported a 7-fold increase in thromboembolism 
(5% per year) with AF compared to patients without AF (0.7% 
per year). The majority of thromboembolic episodes were first 
events and antithrombotic therapy was used in the minority 
(33%) of patients who had had a prior thromboembolism. 
Analysis from a Framingham cohort reported a stroke incidence 
of 4.5% per year with AF and RHD which was a 17-fold increase 
compared to an age, sex and hypertension-matched population 
without AF and RHD. This study likely underestimated the true 
number and incidence of strokes, because AF was only detected 
through biennial ECGs and strokes discovered prior to the 
diagnosis of AF were excluded. 
Traditional CHADS2 score risk factors of stroke (heart failure, 
hypertension, age >75 years, diabetes and prior stroke or 
systemic thromboembolism) have never been tested in the 
valvular AF population.(15)  A contemporary Chinese study of 
130 patients with RHD and stroke (82% had AF) reported a 
high recurrence rate of stroke of 13.6% per year.(7) Based on 
these old studies, RHD and AF carries a risk of thromboembo-
lism equivalent to a non-valvular AF population of CHADS2 
score of 2 or 3; while this risk increases considerably with a 
prior history of TIA/CVA or systemic embolism. 
RISK OF THROMBOEMBOLISM IN 
SINUS RHYTHM
It is well known that MS patients in sinus rhythm are also at 
risk of thromboembolism. A recent systematic review revealed 
6 studies which reported thromboembolic rates in sinus rhythm 
of 0.5 - 5.3% per year.(16) The rates from 4 retrospective studies 
were lower than the 2 prospective studies because of the 
inherent limitation of underreporting in retrospective studies. 
A study by Chiang showed that thromboembolism occurred 
in 9% of patients with sinus rhythm compared to 13% of 
patients in AF.(17) Risk factors for thromboembolism in this 
study included increasing age, presence of LA thrombus, 
decreasing mitral valve area and significant aortic regurgitation. 
Other echocardiographic predictors of thromboemboli include 
the presence of spontaneous echo contrast and a reduced LAA 
emptying flow velocity.(18,19) 
In a recent prospective study of MS and sinus rhythm, transient 
subclinical AF detected by a single Holter monitor was detected 
in 27% of cases and was an independent predictor of syste-
mic embolism with a crude embolic rate of 5.3% per year.(16) 
It is likely that subclinical AF is higher in clinical practice as 
monitoring for AF was limited to 24 hours in this study. Pending 
analyses of the REMEDY and RE-LY AF studies will give us 
further insights into the risk of thromboembolism in the RHD 
AF and sinus rhythm population.
PREVENTION OF THROMBOEMBOLISM
Secondary prevention 
Antithrombotic (vitamin K antagonist (VKA)) therapy has been 
widely used since the 1970s to decrease the risk of recurrent 
thromboembolism in RHD patients (secondary prevention). 
Although observational studies support the use of antithrom-
botic therapy, there have been no randomised trials conducted 
in this population.(20,21) Nevertheless, VKA therapy is clearly 
indicated in this population because of the high risk of recurrent 
thromboembolism.
Primary prevention
Antithrombotic therapy is recommended to prevent thrombo-
embolism in patients with AF without a prior thromboembo-
lism (primary prevention). As RHD was an exclusion criterion 
for all of the contemporary AF trials, recommendations are 
largely based on extrapolation of randomised placebo-con-
trolled trials of nonvalvular AF. Although these trials showed a 
FIGURE 2: Pathogenesis of AF.
Rheumatic mitral valve disease
AF
Structural remodelling
(Artrial Fibrosis and Myocyte atrophy)
Electrical remodelling
(Conduction velocity , refractory periods , 
dispersion of refractoriness , artrial ectopy )
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marked reduction in thromboembolism in patients taking VKAs, 
a similar reduction in risk of thromboembolism in patients with 
RHD cannot be assumed. Despite the inherent bias of non-
randomised studies and the weak methodologies reflecting 
practices at the time, antithrombotic therapy appeared to 
reduce the thromboembolic risk in two observational studies 
of RHD and AF. Fleming reported a low rate of thrombo-
emboli (5 of 217 patients (0.8%)) in patients taking warfarin.(22) 
Another study of 254 patients with AF (including 120 patients 
with mitral valve disease) reported a thromboembolic risk of 
5.46% per year without warfarin versus 0.7% per year for those 
taking warfarin.(23) 
There are unique challenges facing the clinician when prescribing 
antithrombotic therapy in the developing world. Non-com-
pliance to antithrombotic therapy and lack of INR monitoring 
in impoverished settings can increase risks of major bleeding 
and reduce the efficacy of warfarin.(24) Furthermore, for patients 
taking warfarin, percentage of INR values in the therapeutic 
range is also unsatisfactory (<40%).(6) Potential warfarin terato-
genicity is also a major concern for women of childbearing age.
There have been no antithrombotic studies in patients with 
RHD and sinus rhythm. Although risk factors like increasing age, 
LA thrombus, spontaneous echo contrast and an enlarged LA 
have been identified, it remains unclear whether therapy is 
effective in these subgroups.(17) As the majority of RHD patients 
are in sinus rhythm and are potentially at risk, future trials in this 
population group are clearly warranted.  
WHAT DO THE GUIDELINES RECOMMEND?
The current recommendations for antithrombotic therapy and 
RHD are summarised in Table 1. These guidelines are based on 
limited scientific evidence. 
The AHA/ACC 2014 AF guidelines have classified MS as a 
“high risk” condition for thromboembolism, but no specific 
recommendations are made in this guideline.(25) The ESC 2010 
AF guidelines also classify MS as a “high risk” condition and 
recommend warfarin therapy (class 1A).(26) The AHA/ACC 
2014 valvular heart disease guidelines recommend warfarin in 
patients for MS and AF, prior embolic stroke in sinus rhythm 
and/or left atrial thrombus (Class IB).(27) These guidelines also 
state that warfarin for asymptomatic patients with severe MS 
and LA dimension >55mm, or enlarged LA with spontaneous 
echo contrast on echocardiogram, is controversial. 
These guidelines do not specify recommendations for patients 
with RHD and MR or aortic regurgitation, but these patients 
should probably be considered an MS equivalent. There have 
been no trials of any of the novel oral anti-coagulants (NOACs) 
in haemodynamically-significant valvular AF and none can be 
recommended at this time. Studies of the NOACs (e.g. dabi-
gatran, rivaroxaban and apixaban) have all excluded patients 
with prosthetic heart valves and mitral stenosis. In non-valvular 
AF these agents have shown similar or superior reduction in 
thromboembolic rates compared to warfarin and a better 
safety profile. These agents are particularly attractive in a RHD 
population as INR monitoring is not required. Despite the high 
costs of these drugs and the lack of efficacy in patients with 
prosthetic heart valves, the NOACS have the potential to 
improve patient outcomes in the RHD population and future 
trials are needed. 
RATE VERSUS RHYTHM CONTROL IN 
RHEUMATIC AF
The landmark randomised trials of rate versus rhythm control 
did not include patients with rheumatic AF.(28,29) In the AFFIRM 
trial, <5% of patients had valvular heart disease. A rate control 
strategy (using beta-blockers, calcium blockers and/or digoxin) 
is usually adopted in clinical practice because of the low 
likelihood of maintaining sinus rhythm in the long-term. For 
patients with very symptomatic paroxysmal AF, a rhythm con-
trol strategy using cardioversion and amiodarone can be used. 
A small, underpowered randomised trial of rheumatic AF, using 
amiodarone as a rhythm control strategy, maintained sinus 
rhythm in 69% of patients at 1 year.(30) The poor long-term 
tolerability of amiodarone, and the inability to use class I 
antiarrhythmic drugs (like flecainide) in patients with underlying 
left ventricular dysfunction, often preclude the use of these 
drugs to maintain sinus rhythm. 
A long-term observational study from a single center has 
reported that the Cox-maze III procedure at the time of mitral 
valve surgery is effective in reducing AF over long term follow-
up.(31) With the surgical complexity of the Cox-Maze III pro-
cedure, surgical catheter ablation using saline irrigated catheter 
ablation (SICTRA) has become more attractive. A single 
randomised control trial showed that SICTRA was effective 
RHEUMATIC ATRIAL FIBRILLATION
TABLE 1:  Summary of major guidelines for antithrombotic 
therapy and RHD.
Mitral stenosis 
classifi ed as a high risk 
condition
Mitral stenosis
Mitral stenosis
Mitral stenosis 
• Prior stroke 
• LA thrombus 
•  LA >=55mm 
(severe MS)
•  Spontaneous echo 
contrast
No specifi c 
recommendation
Warfarin (Class I, A)
Warfarin (Class I, B)
Warfarin (Class I, B)
Warfarin (Class I, B)
Controversial
Controversial
Atrial fi brillation
AHA/ACC/HRS 2014 
AF guidelines 
(January, et al.)
ESC 2010 AF 
guidelines 
(Camm, et al.)
AHA/ACC 2014 
Valvular Heart Disease 
guidelines 
(Nishimura, et al.)
Sinus rhythm
AHA/ACC 2014 
Valvular Heart Disease 
guidelines 
(Nishimura, et al.) 
155
W
in
te
r 2
01
5
Vo
lu
m
e 
12
 •
 N
um
be
r 3
in restoring sinus rhythm in patients undergoing mitral valve 
replacement without a reduction in survival.(32) A randomised 
trial of SICTRA at the time of mitral valve surgery was superior 
to conventional catheter ablation (pulmonary vein isolation) 
at 6 months post surgery in reducing recurrences of AF.(33) 
Until multicentre trials of catheter ablation in rheumatic AF 
show clinical benefit, catheter ablation of rheumatic AF remains 
investigational. 
CONCLUSION
Rheumatic AF and thromboembolism remain a major cause 
of morbidity and mortality in low and middle income countries. 
Although anticoagulation to prevent thromboembolism is indi-
cated in all patients with rheumatic AF with a low bleeding 
risk, there are unique challenges in prescribing VKA in these 
regions. The safety and efficacy of the NOACs in rheumatic 
AF needs to be explored. Contemporary prospective studies 
on thromboembolic risk in RHD patients in AF and sinus 
rhythm are required. 
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